Colin Bristow
Stock Analyst at UBS
(1.54)
# 3,484
Out of 5,090 analysts
105
Total ratings
38.71%
Success rate
-7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $7.99 | +25.16% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $455.14 | +19.96% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $121.59 | -7.89% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $77.58 | +3.12% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.33 | +50.38% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.43 | -29.82% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $22.88 | -25.70% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $331.45 | -3.76% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.91 | +109.97% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.06 | +7.44% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $100.14 | +19.83% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $182.39 | +10.75% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $2.09 | +667.39% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $720.28 | +52.58% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $22.50 | +642.22% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $1,006.64 | -58.28% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $10.87 | -81.60% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.36 | +662.71% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $226.56 | -35.56% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $52.13 | +43.87% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.70 | +864.75% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.28 | +70.45% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $7.99
Upside: +25.16%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $455.14
Upside: +19.96%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $121.59
Upside: -7.89%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $77.58
Upside: +3.12%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.33
Upside: +50.38%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.43
Upside: -29.82%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $22.88
Upside: -25.70%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $331.45
Upside: -3.76%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.91
Upside: +109.97%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.06
Upside: +7.44%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $100.14
Upside: +19.83%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $182.39
Upside: +10.75%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $2.09
Upside: +667.39%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $720.28
Upside: +52.58%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $22.50
Upside: +642.22%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $1,006.64
Upside: -58.28%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $10.87
Upside: -81.60%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.36
Upside: +662.71%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $226.56
Upside: -35.56%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $52.13
Upside: +43.87%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.70
Upside: +864.75%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.28
Upside: +70.45%